AstraZeneca plans a new investment of $2 billion in the U.S., one of the first major foreign companies to shift spending to the country after Donald Trump’s election win.The decision comes in response to the U.

AstraZeneca Plc raised its annual forecast, driven by strong demand for its blockbuster cancer drugs, and revealed a plan to invest $3.5 billion in the US business by the end of 2026.

KEY TAKEAWAYS British drugmaker AstraZeneca increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the end of 2026.

AstraZeneca (NASDAQ:AZN) said it plans to spend $3.5B to expanding its research and manufacturing capabilities in the United States by the end of 2026. The U.K. drugmaker said the investment was part of its initiative to achieve $80B in total revenue by 2030.